Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Colorcon
McKesson
Dow
McKinsey

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR VASOTEC


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Vasotec

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00248807 ↗ A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury. Completed US Department of Veterans Affairs N/A 2005-10-01 The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.
NCT00248807 ↗ A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury. Completed VA Office of Research and Development N/A 2005-10-01 The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.
NCT00741156 ↗ The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution Completed The Hospital for Sick Children Phase 3 2008-07-01 The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
NCT00895414 ↗ Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer Completed Masonic Cancer Center, University of Minnesota N/A 2009-04-01 RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Enalapril maleate may help protect heart cells from the side effects of chemotherapy. It is not yet known whether giving enalapril maleate before or after doxorubicin hydrochloride is more effective in treating women with breast cancer. PURPOSE: This randomized clinical trial is studying giving enalapril maleate together with doxorubicin hydrochloride to see how well it works in treating women with breast cancer.
NCT01413542 ↗ Pharmacogenetics of Ace Inhibitor-Associated Angioedema Completed Vanderbilt University N/A 2011-11-01 The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.
NCT01669434 ↗ Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery Completed University of Nebraska Phase 4 2015-06-01 Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience better postoperative control of hypertension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience less acute renal failure than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vasotec

Condition Name

Condition Name for Vasotec
Intervention Trials
Hypertension 3
Metastatic Malignant Melanoma 1
Orthostatic Hypotension 1
Spinal Cord Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vasotec
Intervention Trials
Hypertension 3
Hypotension 2
Melanoma 1
Wounds and Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vasotec

Trials by Country

Trials by Country for Vasotec
Location Trials
United States 5
Canada 1
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vasotec
Location Trials
Georgia 1
Nebraska 1
Tennessee 1
Minnesota 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vasotec

Clinical Trial Phase

Clinical Trial Phase for Vasotec
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vasotec
Clinical Trial Phase Trials
Completed 5
Terminated 1
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vasotec

Sponsor Name

Sponsor Name for Vasotec
Sponsor Trials
Brigham and Women's Hospital 2
University of Nebraska 1
Norwegian Cancer Society 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vasotec
Sponsor Trials
Other 11
U.S. Fed 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Johnson and Johnson
McKesson
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.